Skip to Main Content

This chapter deals with defects in the catabolism of gamma-aminobutyric acid (GABA), with defects in receptors of neurotransmitters (GABA and glycine) and in monoamine metabolism. (Glutamine synthase deficiency is discussed in Chapter 145, pyridoxine responsive disorders in Chapter 149, and glycine/serine disorders in Chapter 139.)

Two genetic defects are known in GABA catabolism (Fig. 141-1): the extremely rare, severe, and untreatable GABA transaminase deficiency, and the much more frequent and, to some extent, treatable succinic semialdehyde dehydrogenase (SSADH) deficiency.

Figure 141-1.

Brain metabolism of GABA. B6:pyridoxal phosphate coenzyme; 1: GABA transaminase; 2: succinic semialdehyde dehydrogenase. Enzyme defects are indicated by solid red bars.

Hyperekplexia is a dominantly inherited defect in subunits of the glycine receptor (α1 and β) and in the receptor-associated protein gephyrin. This disease is characterized by excessive startle responses, which are treatable with clonazepam. Mutant GABAA receptor γ-2 subunit causes absence epilepsy and febrile seizures.

Nine defects have been reported in the metabolism of monoamines (Figs. 141-2 and 141-3): five in the synthesis of the cofactor tetrahydrobiopterin, tyrosine-hydroxylase (TH) deficiency, aromatic amino acid decarboxylase (AADC) deficiency, dopamine β-hydroxylase (DBH) deficiency, and monoamine oxidase A (MAO-A) deficiency. All are associated with neurological symptoms except DBH deficiency (orthostatic hypotension). With the exception of MAO-A deficiency, they are more or less efficiently treatable.

Figure 141-2.

Monoamine metabolism. 5-HTRP: 5-hydroxytryptophan; BH4: tetrahydrobiopterin; B6: pyridoxal phosphate coenzyme; VMA: vanillylmandelic acid; MHPG: 3-methoxy-4-hydroxyphenylglycol; HVA: homovanillic acid; 5-HIAA: 5-hydroxyindole acetic acid; 1: tyrosine hydroxylase; 2: aromatic L-amino acid decarboxylase; 3: dopamine beta hydroxylase; 4: monoamine oxidase. Enzyme defects are indicated by solid red bars.

Figure 141-3.

Tetrahydrobiopterin metabolism. GTP: guanosine triphosphate; BH4: tetrahydrobiopterin; q-BH2: quinonoid dihydrobiopterin; 1: GTP cyclohydrolase (GTPCH); 2: 6-pyruvoyl tetrahydropterin synthase (PTPS); 3: sepiapterin reductase (SR); 4: pterincarbinolamine reductase (PCBD); 5: dihydropterin reductase (DHPR). Enzyme defects are indicated by solid red bars.

GABA Transaminase Deficiency

Clinical Presentation

GABA transaminase deficiency was reported in 1984 in a brother and sister from a Flemish family. No other patients have been reported. The siblings showed feeding difficulties from birth, often necessitating gavage feeding; profound axial hypotonia; and generalized convulsions. Hyperreflexia was present during the first 6 to 8 months. Psychomotor development was nearly absent. Growth acceleration was present from birth, due to growth hormone hypersecretion. Postmortem examination of the brain showed spongiform leukodystrophy.

Metabolic Derangement

The CSF and plasma concentrations of GABA, GABA conjugates, and β-alanine were increased due to a decrease of GABA transaminase activity. ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.